Avalo Therapeutics, Inc.
NASDAQ:AVTXBiotechnology
Healthcare
$6.70 -2.18%
-$0.34 today
- Market cap
- $387.41M
- Beta
- 0.82
- P/E (TTM)
- -3.6
- EPS (TTM)
- -$4.21
52W Low $4.50High $24.27
Volume 1.58M
Average 1.61M
Income Statement
Follow revenue through to earnings.
Revenue
$59,000.00
FY 2025 · Annual
-86.6% YoYOperating Income
-$72.92M
FY 2025 · Annual
Net Income
-$78.26M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 5.4M | 18.05M | 1.92M | 441K | 59K |
| Cost of Revenue | 1.49M | 3.43M | 1.28M | (366K) | 0 |
| Gross Profit | 3.91M | 14.62M | 640K | 807K | 59K |
| Gross Margin | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% |
| Research & Development | 59.84M | 31.31M | 13.78M | 52.08M | 50.08M |
| Selling, General & Admin | 24.66M | 20.71M | 10.3M | 17.24M | 22.9M |
| Operating Expenses | 86.04M | 52.06M | 27.99M | 69.32M | 72.98M |
| Depreciation & Amortization | 1.66M | 166K | 158K | 169K | 344K |
| EBITDA | (80.5M) | (37.29M) | (23.29M) | (34.85M) | (77.75M) |
| EBITDA Margin | -1491.2% | -206.6% | -1210.3% | -7901.6% | -131779.7% |
| Operating Income | (82.13M) | (37.44M) | (27.35M) | (68.51M) | (72.93M) |
| Operating Margin | -1521.6% | -207.4% | -1421.6% | -15535.6% | -123601.7% |
| Interest Income | 0 | 0 | 0 | 3.32M | 4.35M |
| Interest Expense | 2.39M | 4.17M | 3.42M | 0 | 0 |
| Other Income / Expenses | (2.41M) | (4.19M) | (4.18M) | 33.5M | (5.17M) |
| Income Before Tax | (84.55M) | (41.63M) | (31.53M) | (35.02M) | (78.09M) |
| Pre-Tax Margin | -1566.2% | -230.6% | -1638.8% | -7939.9% | -132362.7% |
| Income Tax Expense | (196K) | 28K | 14K | 114K | 165K |
| Net Income | (84.38M) | (41.66M) | (31.54M) | (35.13M) | (78.26M) |
| Net Margin | -1563.1% | -230.8% | -1639.5% | -7965.8% | -132642.4% |
| EPS (Basic) | (2,330.66) | (1,062.65) | (113.58) | (4.32) | (5.84) |
| EPS (Diluted) | (2,330.66) | (1,062.65) | (113.58) | (3.26) | (5.84) |
| 36.19K | 39.2K | 277.73K | 8.13M | 13.4M | |
| 36.19K | 39.2K | 277.73K | 10.78M | 13.4M |
AVTX Earnings Waterfall · TTM
NASDAQ:AVTX · Revenue to Net Income
Key Ratios
EPS$-5.83
Gross Margin25.0%
Net Margin-5813.6%
P/E Ratio-3.0
P/S Ratio1424.5
Analysis
$59.0K of revenue converted into -$84.7M of net income for the selected period. Gross margin is 25.0% and net margin is -5813.6%, showing how much revenue survives after costs and taxes. EPS is $-5.83, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| S-3ASR | S-3ASR filing | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 |
How much revenue does AVTX generate?
Avalo Therapeutics, Inc. (AVTX) reported $59,000.00 of revenue in fiscal 2025.
Is AVTX profitable?
Avalo Therapeutics, Inc. (AVTX) reported -$78.26M of net income, with a net margin of -132642.4%.
Continue the stock analysis
Jump to another research area for this company.